Allergy Therapeutics (LON:AGY)‘s stock had its “corporate” rating reissued by equities research analysts at FinnCap in a research note issued to investors on Thursday, January 16th, ThisIsMoney.Co.Uk reports.
LON:AGY traded up GBX 0.25 ($0.00) during mid-day trading on Thursday, reaching GBX 11.25 ($0.15). The stock had a trading volume of 224,760 shares, compared to its average volume of 167,682. The business has a 50 day simple moving average of GBX 10.90 and a 200 day simple moving average of GBX 11.44. Allergy Therapeutics has a twelve month low of GBX 8 ($0.11) and a twelve month high of GBX 15.70 ($0.21). The company has a debt-to-equity ratio of 6.49, a quick ratio of 2.13 and a current ratio of 2.77. The firm has a market capitalization of $71.57 million and a price-to-earnings ratio of 22.50.
Allergy Therapeutics Company Profile
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company’s products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Featured Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Allergy Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allergy Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.